The Gastrointestinal Manifestations of Sjögren's Syndrome

The American Journal of Gastroenterology

Volumn 90, Issue 1, 1995, Pages 9-14

  Sheikh, Shahzad H ^a   Shaw‐Stiffel, Thomas A ^a  

^a BRIDGEPORT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENTIROMIDE; CHOLECYSTOKININ; CHOLINERGIC RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR; GASTRIN; MUCIN; MUSCARINIC AGENT; PEPSINOGEN I; PILOCARPINE; SECRETIN;

ATROPHIC GASTRITIS; AUTOIMMUNITY; DENTAL CARIES; DUODENUM ULCER; DYSPEPSIA; DYSPHAGIA; EPIGASTRIC PAIN; ESOPHAGUS DISEASE; HUMAN; LARGE INTESTINE DISEASE; NAUSEA; PANCREAS INSUFFICIENCY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; SMALL INTESTINE DISEASE; XEROSTOMIA; DIGESTIVE SYSTEM DISEASE; PATHOPHYSIOLOGY;

DIGESTIVE SYSTEM DISEASES; HUMAN; SJOGREN'S SYNDROME;

EID: 0028984742     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1995.tb08000.x     Document Type: Review

References (96)

1. Sjögren's syndrome (sicca syndrome): Current issues
2. Zur Kenntnis der Keratoconjunctivitis Sicca (Keratitis filiformis bei hypofunktion der Tranendrusen)
3. Association of Sjögren's syndrome with HLA‐B8
4. Sjögren's syndrome associated with HLA‐Dw3
5. Do viruses contribute to the development of Sjögren's syndrome
6. Sjögren's syndrome and connective tissue disease associated with other immunologic disorders
7. A specific antibody against the epithelium of the salivary ducts in sera of patients with Sjögren's syndrome
8. Interactions of the salivary and gastrointestinal systems
9. Oral manifestations of Sjögren's syndrome
10. Decreased salivary epidermal growth factor in rheumatoid disease: A possible mechanism for increased susceptibility to gastric ulceration
11. Labial minor salivary gland biopsy in Sjögren's disease
12. An oral disease prevention program for patients receiving radiation and chemotherapy
13. Xerostomia: Evaluation of a symptom with increasing significance
14. Mucin containing lozenges in the treatment of intraoral problems associated with Sjögren's syndrome
15. Oral pilocarpine for post‐irradiation xerostomia in patients with head and neck cancer
16. A multicenter, randomized, double‐blind, placebo controlled dose titration study of oral pilocarpine for treatment of radiation induced xerostomia in head and neck cancer patients
17. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction
18. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome
19. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction
20. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction
21. Oesophageal abnormalities in Sjögren's syndrome
22. Esophageal function, radiography and dysphagia in Sjögren's syndrome
23. Abnormal esophageal motility in primary Sjögren's syndrome
24. Oesophageal dysfunction in patients with primary Sjögren's syndrome
25. The gastrointestinal involvement in primary Sjögren's syndrome
26. Otolaryngological aspects of Sjögren's syndrome
27. Achatasia sicca. Juvenile Sjögren's syndrome with achalasia and gastric hyposecretion
28. Sjögren's syndrome. Review of the literature and report of a case with achalasia of the esophagus
29. Esophageal motor function in primary Sjögren's syndrome
30. Esophageal manometric findings in autoimmune rheumatic diseases: Is Scleroderma esophagus a specific entity
31. Cervical esophageal webs in patients with dysphagia
32. Atrophic gastritis in Sjögren's syndrome: Morphologic, biochemical and immunological findings
33. Lymphocytic infiltrations of the gastric mucosa in Sjögren's syndrome. An immunoperoxidase study using monoclonal antibodies in the avidin‐biotin‐peroxidase method
34. Types of atrophic gastritis in patients with primary Sjögren's syndrome
35. Gastric biopsy in patients with Sjögren's syndrome
36. Sjögren's syndrome: A general disease
37. Gastric studies in Sjögren's syndrome
38. Serum pepsinogen 1 in rheumatic diseases. Reduced levels in Sjögren's syndrome
39. Gastric involvement in primary Sjögren's syndrome
40. The histological and secretory changes in the stomach in patients with autoimmunity to gastric parietal cells
41. Sjögren's syndrome in relation to pernicious anemia and idiopathic Addison's disease
42. 12 deficiency
43. Gastric involvement in Sjögren's syndrome simulating early gastric cancer
44. Role of epidermal growth factor in gastroduodenal mucosal protection
45. Immunohistochemical localization of urogastrone to human duodenal and submandibular glands
46. The effect of concentration on hepatic transport of exogenous epidermal growth factor
47. Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: An update
48. Role of submandibular saliva and epidermal growth factor in gastric cytoprotection
49. Role of mucosal prostaglandins and DNA synthesis in gastric cytoprotection by luminal epidermal growth factor
50. Gastric cytoprotection by epidermal growth factor. Role of endogenous prostaglandins and DNA synthesis
51. Cytoprotcctive effect of pentagastrin and epidermal growth factor on stress ulcer formation. Possible role of somatostatin
52. Duodenal ulcer and Sjögren's syndrome in patients with primary biliary cirrhosis: A casual association
53. The morphological characteristics of the changes in the gastrointestinal tract in Sjögren's disease and Sjögren's syndrome
54. Sjögren's syndrome and adult celiac disease
55. Rheumatic complaints as a presenting symptom in patients with celiac disease
56. Sjögren's syndrome and Crohn's disease
57. Sjögren's syndrome and inflammatory bowel disease
58. Carcinoma of the sigmoid colon associated with Sjögren's syndrome
59. Sjögren's syndrome in association with cryptogenic cirrhosis of the liver, Waldenstrom's macroglobulinemia, and adenocarcinoma of the cecum with amyloidosis
60. A case of chronic idiopathic intestinal pseudo‐obstruction with Sjögren's syndrome
61. Sjögren's disease associated with a nutritional deficiency syndrome
62. Keratoconjunctivitis sicca. A review with a survey of 121 additional cases
63. Xerostomia: An often overlooked problem in nutritional assessment
64. Corneal changes in a case of hepatitis
65. Autoimmune liver disease in patients with primary Sjögren's syndrome
66. Sicca complex in liver disease
67. Liver disease in rheumatoid arthritis and Sjögren's syndrome. Prospective study using biochemical and serological markers of hepatic dysfunction
68. Liver disease in Sjögren's syndrome and rheumatoid arthritis
69. Association of mixed connective tissue disease. Sjögren's syndrome and autoimmune hepatitis: Report of a case
70. Sjögren's syndrome: A clinical, pathological and serological study of 62 cases
71. Autoimmune associations in primary biliary cirrhosis
72. Features of Sjögren's syndrome in primary biliary cirrhosis
73. Primary biliary cirrhosis: The prevalence of hypothyroidism and its relationship to thyroid autoanti‐bodies and sicca syndrome
74. Sjögren's syndrome in patients with primary biliary cirrhosis
75. Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis
76. Primary biliary cirrhosis associated with Sjögren's syndrome: Evidence for circulating and tissue‐deposited Ro/Anti Ro immune complexes
77. Chronic pancreatitis, sclerosing cholangitis and sicca complex in two siblings
78. Primary sclerosing cholangitis associated with fibrosis of the submandibular glands and the pancreas
79. Sclerosing cholangitis, chronic pancreatitis, and Sjögren's syndrome: A syndrome complex
80. Primary segmental sclerosing cholangitis associated with Sjögren's syndrome
81. Primary sclerosing cholangitis associated with Sjögren's syndrome, retroperitoneal fibrosis and chronic pancreatitis
82. Extrasalivary lymphoid abnormalities in Sjögren's syndrome (reticulum‐cell sarcoma, “pseudolymphoma”, macroglobulinemia)
83. Pulmonary and gastrointestinal manifestations of Sjögren's syndrome
84. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease
85. Immunological disorders in C virus chronic active hepatitis: A prospective case‐control study
86. Studies of pancreatic function in Sjögren's syndrome
87. The pancreatic involvement in disseminated “collagen” disorders. Studies of pancreatic secretion in patients with scleroderma and Sjögren's disease
88. Pancreatic function in Sjögren's syndrome
89. A controlled study of the exocrine pancreatic function in Sjögren's syndrome and rheumatoid arthritis
90. Pancreatic function in Sjögren's syndrome
91. Specific cellular immune responses to pancreatic antigen in chronic pancreatitis and Sjögren's syndrome
92. Antibodies to pancreatic duct cells in Sjögren's syndrome and rheumatoid arthritis
93. Sensitization against pancreatic antigen in Sjögren's syndrome and chronic pancreatitis
94. Pancreatic autoantibodies and pancreatic function in Sjögren's syndrome
95. Pancreatic ductal morphology and function in primary Sjögren's syndrome
96. Observations on the pathology of Sjögren's syndrome